Sign In
Buy SRPT
$14.86
-0.700 (-4.50%)
At Close: Jul 31, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
08:00am, Saturday, 10'th May 2025
NEW YORK, NY / ACCESS Newswire / May 10, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ:SRPT). Such investors ar
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
10:15am, Friday, 09'th May 2025
NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT). Such inv
Top 3 Health Care Stocks That Are Preparing To Pump This Quarter
07:16am, Friday, 09'th May 2025
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Sarepta Therapeutics to Present at the BofA Securities Health Care Conference
04:30pm, Thursday, 08'th May 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fi
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
08:00am, Thursday, 08'th May 2025
NEW YORK CITY, NY / ACCESS Newswire / May 8, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ:SRPT). Such investor
Sarepta: ELEVIDYS DMD Treatment Setback Brings Downgrade To Hold Rating
02:14pm, Wednesday, 07'th May 2025
Sarepta Therapeutics, Inc.'s gene therapy SRP-9003 for LGMD 2E/R4 subtype progresses, with potential BLA submission in H2 2025, possibly boosting shareholder value. SRPT rating changed from "Strong Bu
Sarepta Therapeutics Stock Sinks On Gloomy Forecast, Analysts Expect Demand To Pick Up
01:07pm, Wednesday, 07'th May 2025
Sarepta Therapeutics Inc. SRPT reported on Tuesday that the first-quarter 2025 loss of $3.42 per share was missing the analyst consensus estimate of losses of 95 cents.
Sarepta Therapeutics: Lowered Elevidys Guidance Warrant Ratings Downgrade
12:14pm, Wednesday, 07'th May 2025
Sarepta Therapeutics, Inc.'s stock is downgraded to Hold due to underperformance, safety concerns with ELEVIDYS, and increased expenses, despite strong long-term fundamentals. Q1 2025 results show mix
SRPT Q1 Earnings Miss, Sales Beat, Stock Slides 21% on '25 View Cut
09:35am, Wednesday, 07'th May 2025
SRPT reports mixed first-quarter 2025 results. The stock plunges after the company significantly lowers its 2025 sales guidance.
Sarepta Therapeutics Analysts Slash Their Forecasts After Q1 Results
09:28am, Wednesday, 07'th May 2025
Sarepta Therapeutics, Inc. SRPT posted a loss for the first quarter on Tuesday.
Sarepta Therapeutics, Mercury Systems, Arista Networks And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
08:10am, Wednesday, 07'th May 2025
U.S. stock futures were higher this morning, with the Dow futures gaining over 300 points on Wednesday.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
08:00am, Wednesday, 07'th May 2025
NEW YORK CITY, NY / ACCESS Newswire / May 7, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ:SRPT). Such investor
Sarepta Therapeutics, Inc. (SRPT) Q1 2025 Earnings Call Transcript
10:41pm, Tuesday, 06'th May 2025
Sarepta Therapeutics, Inc. (NASDAQ:SRPT ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Mary Jenkins - Associate Director, IR Doug Ingram - President and CEO Dallan Murr
Compared to Estimates, Sarepta Therapeutics (SRPT) Q1 Earnings: A Look at Key Metrics
07:00pm, Tuesday, 06'th May 2025
The headline numbers for Sarepta Therapeutics (SRPT) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall St
Sarepta Therapeutics (SRPT) Reports Q1 Loss, Tops Revenue Estimates
06:40pm, Tuesday, 06'th May 2025
Sarepta Therapeutics (SRPT) came out with a quarterly loss of $3.42 per share versus the Zacks Consensus Estimate of $0.35. This compares to earnings of $0.73 per share a year ago.
